Cangrelor

Published Date: 20th January 2020

Publication Authors: Katira R

Introduction

Acute coronary syndrome (ACS) remains a major cause of mortality and morbidity in people with diabetes. Diabetes is a critical risk factor for the development of ACS and its complications.

Guidance on primary coronary intervention (PCI) for ACS from several authorities recommends the use of a P2Y12 inhibitor along with aspirin and anticoagulation if appropriate.

Oral P2Y12 inhibitors such as prasugrel and ticagrelor have several limitations. Cangrelor is an intravenous agent with a rapid onset and offset of action. Furthermore, intravenous administration may be less cumbersome and more acceptable for some patients. Several patients may also suffer from nausea and vomiting, reducing the suitability of oral agents. In addition, several patients undergoing coronary angiography may require urgent coronary artery bypass grafting, which may have to be delayed in order to discontinue an oral P2Y12 agent. A drug with parenteral administration with a quick onset and offset of action may help to counter this issue.

Katira, A; Katira, R. (2019). Cangrelor . Practical Diabetes. 36 (6), 222-223a

« Back